27 September 2022
Incanthera plc
("Incanthera" or the "Company")
Issue of Equity
Incanthera plc (AQSE: INC), the specialist oncology company focused on innovative technologies in dermatology and oncology announces that it has issued 2,302,157 ordinary shares in the Company ("New Ordinary Shares") at a price of
Furthermore, the Company has issued 1,079,136 warrants over ordinary shares, with an exercise price of
It is expected that admission of the shares will become effective at 8.00 a.m. on or around 3 October 2022.
Following admission of the New Ordinary Shares, the Company's enlarged issued share capital will comprise 76,385,028 ordinary shares of
This announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014 (which forms part of domestic
The directors of the Company take responsibility for this announcement.
For further enquiries:
Incanthera plc:
Tim McCarthy, Chairman tim.mccarthy@incanthera.com
Simon Ward, Chief Executive Officer simon.ward@incanthera.com
Suzanne Brocks, Head of Communications suzanne.brocks@incanthera.com |
+44 (0) 7831 675747
+44 (0) 7747 625506
+44 (0) 7776 234600 |
|
|
Aquis Exchange Corporate Adviser: Cairn Financial Advisers LLP Jo Turner/James Lewis |
+44 (0) 20 7213 0880 |
|
|
Broker: Stanford Capital Partners Ltd Patrick Claridge/Tom Price/John Howes/Bob Pountney |
+44 (0) 20 3815 8880 |
Notes to Editors
Incanthera is dedicated to innovative technologies in dermatology and oncology. It seeks to identify and commercialise inspirational therapeutics combined with uniquely targeted delivery systems, for innovative solutions to clinical, commercially relevant unmet needs.
The Company's current lead product and focus is Sol, a potentially innovative topical product for the treatment of solar keratosis and the prevention of skin cancers. The Company is currently focussed upon delivering Sol to a commercial partner.
Originating from the Institute of Cancer Therapeutics ("ICT") at the University of Bradford, the Company has acquired and developed a portfolio of specific cancer-targeting therapeutics, with a strategy to develop each candidate from initial acquisition/discovery to commercially valuable partnerships at the earliest opportunity in its development pathway.
For more information on the Company please visit: www.incanthera.com
@incantheraplc
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.